The OlympiAD trial, conducted by Robson M et al. [25], assessed the efficacy and safety of olaparib, another PARP inhibitor, compared to standard single-agent chemotherapy in women with HER2-negative metastatic BC who also had a germline BRCA1/2 mutation. Here, ERBB2 is linked to breast cancer.